Abstract
The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.
| Original language | English |
|---|---|
| Pages (from-to) | 753-760 |
| Number of pages | 8 |
| Journal | Japanese Journal of Chemotherapy |
| Volume | 44 |
| Issue number | 9 |
| Publication status | Published - 1996 Sep |
| Externally published | Yes |
Fingerprint
Keywords
- amikacin
- imipenem/cilastatin sodium
- rhG-CSF
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases. / Toyama, K.; Yaguchi, M.; Okamoto, Shinichiro; Masuda, Y.; Aoki, I.; Kitahara, M.; Takahashi, Y.; Kawato, M.; Boku, T.; Izawa, K.; Uchida, Y.; Wakasugi, K.; Kikuchi, M.; Tsuruoka, N.; Koike, M.; Ohshima, T.; Kawamura, M.
In: Japanese Journal of Chemotherapy, Vol. 44, No. 9, 09.1996, p. 753-760.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The clinical efficacy of combination therapy with amikacin, imipenem/cilastatin sodium and granulocyte colony-stimulating factor on infection in neutropenic patients with hematologic diseases
AU - Toyama, K.
AU - Yaguchi, M.
AU - Okamoto, Shinichiro
AU - Masuda, Y.
AU - Aoki, I.
AU - Kitahara, M.
AU - Takahashi, Y.
AU - Kawato, M.
AU - Boku, T.
AU - Izawa, K.
AU - Uchida, Y.
AU - Wakasugi, K.
AU - Kikuchi, M.
AU - Tsuruoka, N.
AU - Koike, M.
AU - Ohshima, T.
AU - Kawamura, M.
PY - 1996/9
Y1 - 1996/9
N2 - The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.
AB - The clinical efficacy of combination therapy with amikacin (AMK), imipenem/cilastatin sodium (IPM/CS) and recombinant human granulocyte colony- stimulating factor (G-CSF) was evaluated in 32 neutropenic patients with hematological diseases. Clinical effectiveness was observed in 24 cases (including 3 cases of sepsis), an efficacy rate of 75.0%. The efficacy rate was 90% in the l0 patients with neutrophil counts less than 100/μl at the time of therapeutic evaluation. It was 81.1% (9/11) in patients whose neutrophil counts increased 20% or more during treatment and 66.7% (8/12) in patients whose neutrophil counts increased less than 20%; the difference in efficacy rates was not statistically significant. A clinical efficacy rate of 75.9% was observed in 29 neutropenic patients chosen according to the same criteria as those of the present study from among patients who were treated with AMK plus IPM/CS in a previous study (the historical controls . When the results in the historical control group were compared with those in the (G- CSF group, there was no significant difference in efficacy rate, profile of body temperature or duration of fever. The results suggest that combination therapy with AMK and IPM/CS is very effective in treating infections in neutropenic patients, with or without G-CSF.
KW - amikacin
KW - imipenem/cilastatin sodium
KW - rhG-CSF
UR - http://www.scopus.com/inward/record.url?scp=10244257586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10244257586&partnerID=8YFLogxK
M3 - Article
VL - 44
SP - 753
EP - 760
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
IS - 9
ER -